Literature DB >> 30027226

Association of Tumor Size With Histologic and Clinical Outcomes Among Patients With Cytologically Indeterminate Thyroid Nodules.

Pablo Valderrabano1, Laila Khazai2, Zachary J Thompson3, Kristen J Otto1, Julie E Hallanger-Johnson1, Christine H Chung1, Barbara A Centeno2, Bryan McIver1.   

Abstract

Importance: Tens of thousands of unnecessary operations are performed each year for diagnostic purposes among patients with cytologically indeterminate thyroid nodules. Whereas a diagnostic lobectomy is recommended for most patients with solitary indeterminate thyroid nodules, a total thyroidectomy is preferred for nodules larger than 4 cm. Objective: To determine whether histologic or clinical outcomes of indeterminate thyroid nodules 4 cm or larger are worse than those for nodules smaller than 4 cm, thus justifying a more aggressive initial surgical approach. Design, Setting, and Participants: In this retrospective cohort study, 652 indeterminate thyroid nodules (546 nodules <4 cm and 106 nodules ≥4 cm) with surgical follow-up were consecutively evaluated at an academic cancer center from October 1, 2008, through April 30, 2016. Exposure: Tumor size. Main Outcomes and Measures: Differences in cancer rates, rates of invasive features, cancer aggressiveness, and response to therapy between indeterminate thyroid nodules smaller than 4 cm and 4 cm or larger.
Results: A total of 652 indeterminate thyroid nodules (546 nodules <4 cm and 106 nodules ≥4 cm) from 589 patients (mean [SD] age, 53.1 [13.8] years; 453 [76.9%] female) were studied. No differences were found in the baseline characteristics of patients or nodules between the 2 size groups. Tumor size was not associated with the cancer rate as a categorical (140 of 546 [25.6%] for nodules <4 cm and 33 of 106 [31.1%] for nodules ≥4 cm; effect size, 0.05; 95% CI, 0.002-0.12) or continuous (odds ratio [OR], 1.03; 95% CI, 0.92-1.15) variable. No association was found between nodule size and prevalence of extrathyroidal extension, positive margins, lymphovascular invasion, lymph node metastasis, or distant metastasis. Most malignant tumors were low risk in both size groups (70% in the nodules <4 cm and 72% in the nodules ≥4 cm), and tumor size was not associated with tumor aggressiveness as a categorical (effect size, 0.10; 95% CI, 0.03-0.31) or continuous variable (OR for intermediate-risk cancer, 0.91; 95% CI, 0.72-1.14; OR for high-risk cancer, 1.43; 95% CI, 0.96-2.15). At the last follow-up visit, 88 of 105 patients (83.8%) with malignant tumors in the smaller than 4 cm group and 21 of 25 (84.0%) in the 4 cm or greater group had no evidence of disease, and tumor size was not associated with response to therapy (effect size, 0.13; 95% CI, 0.07-0.33). Conclusions and Relevance: Most indeterminate thyroid nodules are benign or low-risk malignant tumors regardless of tumor size. In the absence of other indications for total thyroidectomy, this study suggests that a thyroid lobectomy is sufficient initial treatment for most solitary cytologically indeterminate thyroid nodules independent of the tumor size.

Entities:  

Mesh:

Year:  2018        PMID: 30027226      PMCID: PMC6233620          DOI: 10.1001/jamaoto.2018.1070

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  38 in total

1.  Surgery for papillary thyroid carcinoma: is lobectomy enough?

Authors:  Abie H Mendelsohn; David A Elashoff; Elliot Abemayor; Maie A St John
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-11

Review 2.  BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and meta-analysis.

Authors:  Pierpaolo Trimboli; Giorgio Treglia; Emma Condorelli; Francesco Romanelli; Anna Crescenzi; Massimo Bongiovanni; Luca Giovanella
Journal:  Clin Endocrinol (Oxf)       Date:  2015-05-22       Impact factor: 3.478

3.  Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.

Authors:  Lisa A Radkay; Simion I Chiosea; Raja R Seethala; Steven P Hodak; Shane O LeBeau; Linwah Yip; Kelly L McCoy; Sally E Carty; Karen E Schoedel; Marina N Nikiforova; Yuri E Nikiforov; N Paul Ohori
Journal:  Cancer Cytopathol       Date:  2014-08-12       Impact factor: 5.284

4.  The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories.

Authors:  Kyle C Strickland; Brooke E Howitt; Ellen Marqusee; Erik K Alexander; Edmund S Cibas; Jeffrey F Krane; Justine A Barletta
Journal:  Thyroid       Date:  2015-07-29       Impact factor: 6.568

5.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

6.  Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients.

Authors:  David A Kleiman; Matthew J Sporn; Toni Beninato; Michael J Crowley; Anvy Nguyen; Alessia Uccelli; Theresa Scognamiglio; Rasa Zarnegar; Thomas J Fahey
Journal:  Cancer       Date:  2012-12-21       Impact factor: 6.860

7.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

8.  Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.

Authors:  Yuri E Nikiforov; Sally E Carty; Simon I Chiosea; Christopher Coyne; Umamaheswar Duvvuri; Robert L Ferris; William E Gooding; Steven P Hodak; Shane O LeBeau; N Paul Ohori; Raja R Seethala; Mitchell E Tublin; Linwah Yip; Marina N Nikiforova
Journal:  Cancer       Date:  2014-09-10       Impact factor: 6.860

9.  Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons.

Authors:  Adam Hauch; Zaid Al-Qurayshi; Gregory Randolph; Emad Kandil
Journal:  Ann Surg Oncol       Date:  2014-06-19       Impact factor: 5.344

10.  The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease.

Authors:  Teresa Rago; Maria Scutari; Francesco Latrofa; Valeria Loiacono; Paolo Piaggi; Ivo Marchetti; Rossana Romani; Fulvio Basolo; Paolo Miccoli; Massimo Tonacchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2014-04-07       Impact factor: 5.958

View more
  2 in total

1.  Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.

Authors:  Whitney S Goldner; Trevor E Angell; Sallie Lou McAdoo; Joshua Babiarz; Peter M Sadow; Fadi A Nabhan; Christian Nasr; Richard T Kloos
Journal:  Thyroid       Date:  2019-09-27       Impact factor: 6.568

2.  Thyroid nodules with indeterminate cytology: association between nodule size, histopathological characteristics and clinical outcome in differentiated thyroid carcinomas - a multicenter retrospective cohort study on 761 patients.

Authors:  Federico Cozzani; Dario Bettini; Matteo Rossini; Elena Bonati; Simona Nuzzo; Tommaso Loderer; Giuseppe Pedrazzi; Alberto Zaccaroni; Paolo Del Rio
Journal:  Updates Surg       Date:  2021-06-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.